1.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Ang...
by Dahlöf, Björn
The Lancet (British edition), 2005, Vol.366 (9489), p.895-906
2.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoprox...
by DeJesus, Edwin
The Lancet (British edition), 2012, Vol.379 (9835), p.2429-2438
3.
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
by Parker, Catriona, PhD
The Lancet (British edition), 2010, Vol.376 (9757), p.2009-2017
4.
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
by Bergenstal, Richard M, Dr
The Lancet (British edition), 2010, Vol.376 (9739), p.431-439
5.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a random...
by Sax, Paul E, Dr
The Lancet (British edition), 2012, Vol.379 (9835), p.2439-2448
6.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose...
by Cunningham, David, Prof
The Lancet (British edition), 2013, Vol.381 (9880), p.1817-1826
7.
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
by The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
The Lancet (British edition), 2001, Vol.358 (9282), p.605-613
8.
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-labe...
by Schmitz, Norbert, Prof
The lancet oncology, 2012, Vol.13 (12), p.1250-1259
9.
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an...
by Mizokami, Masashi, Prof
The Lancet infectious diseases, 2015, Vol.15 (6), p.645-653
10.
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in a...
by Boyd, M A
The Lancet (British edition), 2013, Vol.381 (9883), p.2091-2099
11.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
by Swedberg, Karl, Prof
The Lancet (British edition), 2010, Vol.376 (9744), p.875-885
12.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
13.
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
by Keystone, Edward C
Annals of the rheumatic diseases, 2015, Vol.74 (2), p.333-340
14.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase...
by Kowdley, Kris V, Dr
The Lancet (British edition), 2013, Vol.381 (9883), p.2100-2107
15.
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
by Blank, Christian U
Nature medicine, 2018, Vol.24 (11), p.1655-1661
16.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
by Drucker, Daniel J
The Lancet (British edition), 2006, Vol.368 (9548), p.1696-1705
17.
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr
The Lancet (British edition), 2012, Vol.379 (9829), p.1893-1901
18.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b stud...
by Clotet, Bonaventura, Dr
The Lancet (British edition), 2014, Vol.383 (9936), p.2222-2231
19.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplanta...
by Cook, Gordon, Prof
The lancet oncology, 2014, Vol.15 (8), p.874-885
20.
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
by Ruslami, Rovina, PhD
The Lancet infectious diseases, 2013, Vol.13 (1), p.27-35
